Literature DB >> 26407563

Hormonal contraception and pelvic floor function: a systematic review.

Rita Champaneria1, Ruben Mamprin D'Andrea2, Pallavi M Latthe3.   

Abstract

INTRODUCTION AND HYPOTHESIS: Hormonal contraceptive use is common practice worldwide. Although the effects of hormone treatments in the pelvic region are well established, there is no clear evidence regarding their effects on incontinence, bladder, bowel, vaginal and sexual symptoms in premenopausal women. We hypothesized that hormonal contraceptives affect pelvic floor function. We therefore performed a comprehensive systematic review of published studies to determine the influence of hormonal contraception on pelvic floor functions.
METHODS: Electronic literature databases were searched from database inception to March 2015. Keywords and medical subject headings searched for included terms and word variations for 'contraception', and 'bowel', 'vaginal', 'sexual' and 'urinary' symptoms. Studies were eligible if they looked at these symptoms in women taking hormonal contraception. Two reviewers independently screened studies for inclusion, and extracted data on study characteristics, quality and results. Data were combined where possible.
RESULTS: Of the 429 citations identified, 13 studies were included in the review. Data were meta-analysed where possible and presented as prevalence. The results indicate statistically significant links between interstitial cystitis and oral contraceptive use at any point (ever) (OR 2.31, 95 % CI 1.03 - 5.16; p = 0.04) and vulvar vestibulitis and current oral contraceptive use (OR 2.10, 95 % CI 1.26 - 3.49; p = 0.004). The evidence is unclear in other areas.
CONCLUSIONS: Our results indicate that oral contraceptives may have an effect on pelvic floor function. They could increase the risk of painful bladder and vulvar vestibulitis, but their effect on dyspareunia is inconsistent. However, robustly collected prospective data to establish causal associations are needed.

Entities:  

Keywords:  Bowel; Contraception; Oral; Sexual; Urinary; Vaginal

Mesh:

Substances:

Year:  2015        PMID: 26407563     DOI: 10.1007/s00192-015-2833-3

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  22 in total

1.  Estrogen and neuroinflammation.

Authors:  D E Bjorling; Z Y Wang
Journal:  Urology       Date:  2001-06       Impact factor: 2.649

2.  Sexuality and reproductive risk factors for interstitial cystitis/painful bladder syndrome in women.

Authors:  John W Warren; Daniel J Clauw; Ursula Wesselmann; Patricia W Langenberg; Fred M Howard; Vadim Morozov
Journal:  Urology       Date:  2011-01-07       Impact factor: 2.649

3.  Interstitial cystitis is associated with vulvodynia and sexual dysfunction--a case-control study.

Authors:  Barbara Gardella; Daniele Porru; Rossella E Nappi; Maria Diletta Daccò; Alessia Chiesa; Arsenio Spinillo
Journal:  J Sex Med       Date:  2011-04-07       Impact factor: 3.802

4.  Urinary incontinence in the 12-month postpartum period.

Authors:  Kathryn L Burgio; Halina Zyczynski; Julie L Locher; Holly E Richter; David T Redden; Kate Clark Wright
Journal:  Obstet Gynecol       Date:  2003-12       Impact factor: 7.661

Review 5.  Oestrogen therapy for urinary incontinence in post-menopausal women.

Authors:  June D Cody; Madeleine Louisa Jacobs; Karen Richardson; Birgit Moehrer; Andrew Hextall
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

6.  Use of oral contraceptive pills and vulvar vestibulitis: a case-control study.

Authors:  Céline Bouchard; Jacques Brisson; Michel Fortier; Carol Morin; Caty Blanchette
Journal:  Am J Epidemiol       Date:  2002-08-01       Impact factor: 4.897

7.  Depo-Provera use in an Australian metropolitan practice.

Authors:  I S Fraser; G J Dennerstein
Journal:  Med J Aust       Date:  1994-05-02       Impact factor: 7.738

8.  Risk of urinary incontinence symptoms in oral contraceptive users: a national cohort study from the Swedish Twin Register.

Authors:  Anastasia Iliadou; Ian Milsom; Nancy L Pedersen; Daniel Altman
Journal:  Fertil Steril       Date:  2008-08-15       Impact factor: 7.329

9.  Oral contraceptive use and risk of vulvodynia: a population-based longitudinal study.

Authors:  B D Reed; S D Harlow; L J Legocki; M E Helmuth; H K Haefner; B W Gillespie; A Sen
Journal:  BJOG       Date:  2013-08-13       Impact factor: 6.531

10.  Effects of estrogens and bladder inflammation on mitogen-activated protein kinases in lumbosacral dorsal root ganglia from adult female rats.

Authors:  Ying Cheng; Janet R Keast
Journal:  BMC Neurosci       Date:  2009-12-28       Impact factor: 3.288

View more
  3 in total

1.  Hormonally Active Contraceptives, Part II: Sociological, Environmental, and Economic Impact.

Authors:  William V Williams; Joel Brind; Laura Haynes; Michael D Manhart; Hanna Klaus; Angela Lanfranchi; Gerard Migeon; Michael Gaskins; Elvis I Šeman; Lester Ruppersberger; Kathleen M Raviele
Journal:  Linacre Q       Date:  2021-04-21

2.  Applying concepts of life course theory and life course epidemiology to the study of bladder health and lower urinary tract symptoms among girls and women.

Authors:  Sonya S Brady; Amanda Berry; Deepa R Camenga; Colleen M Fitzgerald; Sheila Gahagan; Cecilia T Hardacker; Bernard L Harlow; Jeni Hebert-Beirne; D Yvette LaCoursiere; Jessica B Lewis; Lisa K Low; Jerry L Lowder; Alayne D Markland; Gerald McGwin; Diane K Newman; Mary H Palmer; David A Shoham; Ariana L Smith; Ann Stapleton; Beverly R Williams; Siobhan Sutcliffe
Journal:  Neurourol Urodyn       Date:  2020-03-02       Impact factor: 2.696

3.  Hormonally Active Contraceptives Part I: Risks Acknowledged and Unacknowledged.

Authors:  William V Williams; Joel Brind; Laura Haynes; Michael D Manhart; Hanna Klaus; Angela Lanfranchi; Gerard Migeon; Mike Gaskins; Elvis I Seman; Lester Ruppersberger; Kathleen M Raviele
Journal:  Linacre Q       Date:  2021-01-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.